Trials / Completed
CompletedNCT02808312
Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function
A Phase 1 Open-Label, Parallel-Group, Adaptive, Single-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of GS-9674 in Subjects With Normal and Impaired Hepatic Function
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to evaluate the single-dose pharmacokinetics of cilofexor in adults with impaired hepatic function relative to matched, healthy controls with normal hepatic function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cilofexor | Tablet(s) administered orally in a fed state on Day 1 |
Timeline
- Start date
- 2016-07-13
- Primary completion
- 2018-10-16
- Completion
- 2018-10-16
- First posted
- 2016-06-21
- Last updated
- 2021-01-07
- Results posted
- 2020-09-30
Locations
5 sites across 2 countries: United States, New Zealand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02808312. Inclusion in this directory is not an endorsement.